BPL-003 Shows Rapid, Durable Relief for Treatment-Resistant Depression Patients on SSRIs

Two days after a single intranasal dose of BPL-003, two-thirds of treatment-resistant depression patients showed a clinically meaningful improvement in symptoms while continuing their existing SSRI therapy, according to peer-reviewed Phase 2a results published in CNS Drugs by AtaiBeckley Inc. The finding, notable for its speed in a population that typically waits months to gauge whether a new medication is working, adds a second data layer to a growing clinical program behind the experimental compound, known generically as mebufotenin benzoate.

Treatment-resistant depression affects roughly one in three patients diagnosed with major depressive disorder, a group in which two or more adequate antidepressant courses have failed to produce remission. Standard SSRIs can take four to six weeks before delivering any measurable symptom relief, and many patients who do respond never fully recover. The urgency of finding faster-acting, more durable options has made the TRD space one of the most closely watched corners of clinical psychiatry.

The Part 2 dataset, drawn from the company's ongoing four-part open-label Phase 2a program (NCT05660642), enrolled 12 adults with moderate-to-severe TRD who remained on stable SSRI therapy throughout the study. Participants were divided into two cohorts of six and received a single intranasal dose of either 10 mg or 12 mg. A 66.7% antidepressant response rate, defined as at least a 50% reduction from baseline on the Montgomery-Åsberg Depression Rating Scale, was observed at Day 2 in both cohorts. More strikingly, 83% of patients in the 10 mg group maintained that response through Day 85, while 66.7% of the 12 mg group did the same. Patients were discharged within an average of less than two hours after dosing.

Chief Medical Officer Kevin Craig framed the SSRI compatibility as the study's defining contribution: "This study provides the first Phase 2a evidence that BPL-003 can be administered alongside SSRIs without compromising efficacy or safety, a meaningful advance given that many TRD patients remain on chronic SSRI therapy." That point carries clinical weight because many psychedelic-adjacent trial protocols require patients to undergo an SSRI washout period before dosing, a barrier that disqualifies or complicates treatment for a large share of the target population.

The Part 2 results reinforce an earlier signal. Part 1, published in the Journal of Psychopharmacology in March, evaluated a 10 mg monotherapy dose in 12 patients not on SSRIs and found a mean 12.6-point MADRS reduction by Day 2, sustained to Day 85. CEO Srinivas Rao cited that figure when the company reported it was targeting Phase 3 initiation in Q2 2026, following a successful End-of-Phase 2 meeting with the FDA in March 2026. BPL-003 holds FDA Breakthrough Therapy Designation, awarded in October 2025.

What Part 2 cannot settle is equally important to state clearly. The trial was open-label, meaning neither patients nor investigators were blinded, which is known to inflate estimates of benefit relative to randomized, placebo-controlled designs. The 12-patient sample is too small to detect uncommon adverse events, and while all reported side effects were classified as mild to moderate, the profile of a psychedelic-adjacent compound in a broader population remains an open question. The durability observed at 12 weeks, while promising, has not yet been tested against a placebo comparator across the multi-hundred-patient scale that regulators require.

With two parallel Phase 3 trials targeting a Q2 2026 start and two additional parts of the Phase 2a program still ongoing, the next 12 to 18 months will determine whether a 48-hour response in 12 patients is the start of a genuinely new treatment category, or an early signal that larger, more rigorous trials quietly revise downward.